UBS Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-7,301
| Closed | -$42.6K | – | 11341 |
|
|
2022
Q4 | $42.6K | Sell |
7,301
-6,560
| -47% | -$34.5K | ﹤0.01% | 6917 |
|
|
2022
Q3 | $94K | Buy |
13,861
+4,142
| +43% | +$25.1K | ﹤0.01% | 5763 |
|
|
2022
Q2 | $41K | Sell |
9,719
-6,347
| -40% | -$25.1K | ﹤0.01% | 6083 |
|
|
2022
Q1 | $54K | Sell |
16,066
-2,383
| -13% | -$7.55K | ﹤0.01% | 6428 |
|
|
2021
Q4 | $58K | Sell |
18,449
-10,216
| -36% | -$34K | ﹤0.01% | 6773 |
|
|
2021
Q3 | $94K | Buy |
28,665
+3,121
| +12% | +$10.9K | ﹤0.01% | 5873 |
|
|
2021
Q2 | $108K | Sell |
25,544
-11,981
| -32% | -$50.7K | ﹤0.01% | 5821 |
|
|
2021
Q1 | $188K | Buy |
37,525
+782
| +2% | +$6.32K | ﹤0.01% | 5535 |
|
|
2020
Q4 | $465K | Buy |
36,743
+2,519
| +7% | +$28.7K | ﹤0.01% | 4663 |
|
|
2020
Q3 | $336K | Sell |
34,224
-17,332
| -34% | -$171K | ﹤0.01% | 4464 |
|
|
2020
Q2 | $513K | Sell |
51,556
-7,397
| -13% | -$70.9K | ﹤0.01% | 4122 |
|
|
2020
Q1 | $521K | Sell |
58,953
-19,676
| -25% | -$194K | ﹤0.01% | 3923 |
|
|
2019
Q4 | $726K | Sell |
78,629
-3,279
| -4% | -$23.2K | ﹤0.01% | 4508 |
|
|
2019
Q3 | $482K | Buy |
81,908
+14,084
| +21% | +$149K | ﹤0.01% | 4593 |
|
|
2019
Q2 | $814K | Buy |
67,824
+5,643
| +9% | +$60.7K | ﹤0.01% | 3914 |
|
|
2019
Q1 | $751K | Buy |
62,181
+2,245
| +4% | +$33.1K | ﹤0.01% | 3773 |
|
|
2018
Q4 | $752K | Sell |
59,936
-17,040
| -22% | -$235K | ﹤0.01% | 3930 |
|
|
2018
Q3 | $1.14M | Sell |
76,976
-212
| -0.3% | -$3.33K | ﹤0.01% | 3723 |
|
|
2018
Q2 | $1.3M | Sell |
77,188
-48,660
| -39% | -$945K | ﹤0.01% | 3553 |
|
|
2018
Q1 | $2.88M | Sell |
125,848
-167,006
| -57% | -$3.71M | ﹤0.01% | 2802 |
|
|
2017
Q4 | $7.58M | Buy |
292,854
+34,420
| +13% | +$693K | ﹤0.01% | 1963 |
|
|
2017
Q3 | $3.81M | Buy |
258,434
+160,449
| +164% | +$2.33M | ﹤0.01% | 2489 |
|
|
2017
Q2 | $1.37M | Sell |
97,985
-16,081
| -14% | -$237K | ﹤0.01% | 3347 |
|
|
2017
Q1 | $1.95M | Sell |
114,066
-62,385
| -35% | -$748K | ﹤0.01% | 2965 |
|
|
2016
Q4 | $1.82M | Sell |
176,451
-4,124
| -2% | -$37.7K | ﹤0.01% | 2995 |
|
|
2016
Q3 | $1.82M | Sell |
180,575
-38,617
| -18% | -$422K | ﹤0.01% | 2924 |
|
|
2016
Q2 | $2.46M | Sell |
219,192
-11,446
| -5% | -$146K | ﹤0.01% | 2597 |
|
|
2016
Q1 | $3.15M | Sell |
230,638
-16,877
| -7% | -$243K | ﹤0.01% | 2276 |
|
|
2015
Q4 | $4.7M | Sell |
247,515
-33,059
| -12% | -$718K | ﹤0.01% | 2017 |
|
|
2015
Q3 | $5.27M | Sell |
280,574
-2,224
| -0.8% | -$37.8K | ﹤0.01% | 1875 |
|
|
2015
Q2 | $4.21M | Sell |
282,798
-3,001
| -1% | -$45.7K | ﹤0.01% | 2247 |
|
|
2015
Q1 | $4.33M | Buy |
285,799
+13,779
| +5% | +$192K | ﹤0.01% | 2198 |
|
|
2014
Q4 | $3.62M | Buy |
+272,020
| New | +$3.51M | ﹤0.01% | 2363 |
|
UBS Group's CNCE Position: Q1 2023 in Review
UBS Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 7,301 shares — an estimated $42.6K sold.
UBS Group first reported a position in CNCE in Q4 2014 and held it in 33 quarters. The position peaked at $7.58M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- UBS Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 7,301 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $42.6K.
- UBS Group first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 33 quarters.
- UBS Group's Concert Pharmaceuticals, Inc. position peaked at $7.58M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.